Kalled Musallam: A Comprehensive Review of Thalassemia
Kalled Musallam, Group Chief Research Officer at Burjeel Holdings and Deputy CEO and Chief of Cellular and Gene Therapy and Hematology at Burjeel Cancer Institute, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nature Reviews Disease Primers, adding:
“Pleased to share our new comprehensive review on thalassemia published today in Nature Reviews Disease Primers, one of the leading journals from the Nature portfolio (impact factor 80), which will hopefully provide thalassemia with greater visibility across the broader scientific and medical community.”
Title: Thalassaemia
Authors: Frédéric B. Piel, Mariane de Montalembert, Reena Das, Kevin H. M. Kuo, Ali T. Taher, Khaled M. Musallam, Marsha Treadwell, Suthat Fucharoen, Michael Angastiniotis, Douglas Higgs, Elliott Vichinsky, Maria Domenica Cappellini, Lucia De Franceschi
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 21, 2026, 21:12Ammar Al Awawdeh: Bridging the Hemostatic Gap – Functional Platelet Salvage in CPB
-
Jul 21, 2026, 19:44Shinya Goto: JCS/JPCPHS 2025 Guideline Now Available in English
-
Jul 21, 2026, 19:43Abdul Mannan: Why Is HbS or HbD Approximately 40% in Heterozygotes Rather Than 50%?
-
Jul 21, 2026, 19:42Haemophilia Maintains a 2025 Impact Factor of 3.0 – WFH
-
Jul 21, 2026, 19:41Wolfgang Miesbach: SR604 Restores Thrombin Generation Where It Is Needed
-
Jul 21, 2026, 19:40Filmon Tesfay: Our New Case Report on Cerebral Venous Thrombosis Is Now Published
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes